Jagsonpal Pharmaceuticals (JAGSNPHARM) investor relations material

Executive summary

• Q4 FY 2026 saw a strong recovery with 10% revenue growth year-on-year after two flat quarters, driven by operational execution and MR productivity improvements.

• FY 2026 revenue grew 7% year-on-year, with operating net profit before exceptional items rising 19%, reflecting disciplined execution and financial management.

• Outperformed the Indian Pharma Market (IPM), with 12.2% MAT growth and 14.2% Q4 growth against industry growth of 10.5%.

• Top 10 brands contributed 58%-60% of sales, with nine ranked in the top five of their categories; gynecology and dermatology led growth.

• Audited standalone financial results for the quarter and year ended March 31, 2026, were approved, with an unmodified audit opinion issued by the statutory auditors.

Financial highlights

• FY26 revenue: INR 287 crore (₹2,872 Mn), up 7% YoY; Q4 FY26 revenue: INR 64 crore (₹642 Mn), up 10% YoY.

• FY26 EBITDA: INR 61 crore (₹609 Mn, 21% margin); Q4 EBITDA: INR 11 crore (₹106 Mn, 16.4% margin).

• FY26 operational PAT: INR 45 crore (₹446 Mn, up 19% YoY, 16% margin); Q4 PAT: INR 9 crore (₹88 Mn, up 31%-33% YoY, margin 13.6%-14%).

• Gross margin for the year above 64%, stable versus prior year; minor fluctuations due to product mix.

• Cash and equivalents at INR 190 crore (₹1,907 Mn) as of March 31, 2026.

Outlook and guidance

• Management maintains guidance of 1.5x IPM growth, translating to 12%-15% top-line growth, with continued focus on MR productivity and brand investments.

• Focus on organic growth via improved MR productivity, strengthening key brands, and launching new products; exploring value-accretive inorganic opportunities.

• Continued strong cash generation and improving ROCE/ROE expected in FY27 and beyond.